Takefumi Suzuki

Summary

Country: Japan

Publications

  1. ncbi Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz)
    Takefumi Suzuki
    Keio University, School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Schizophr Res 106:328-36. 2008
  2. ncbi Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation
    Takefumi Suzuki
    Department of Neuropsychiatry, Keio University, School of Medicine, Tokyo, Japan
    Psychiatry Res 197:1-6. 2012
  3. ncbi Factors associated with response to clozapine in schizophrenia: a review
    Takefumi Suzuki
    Keio University, School of Medicine, Department of Neuropsychiatry, 35, Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Psychopharmacol Bull 44:32-60. 2011
  4. ncbi Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review
    Takefumi Suzuki
    Keio University, School of Medicine, Department of Neuropsychiatry, 35, Shinanomachi, Shinjuku ku, Tokyo, Japan
    Psychopharmacol Bull 44:18-31. 2011
  5. ncbi Treatment resistant schizophrenia and response to antipsychotics: a review
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program, Toronto, Ontario, Canada
    Schizophr Res 133:54-62. 2011
  6. ncbi Treatment target in schizophrenia: a critical review and a clinical suggestion
    Takefumi Suzuki
    Keio University, School of Medicine, Department of Neuropsychiatry, Shinjuku ku, Tokyo, Japan
    Psychopharmacol Bull 41:80-102. 2008
  7. ncbi A potentially aborted neuroleptic malignant syndrome following seclusion against uncontrollable water intoxication
    Takefumi Suzuki
    Department of Neuro Psychiatry, Keio University, School of Medicine, Shinjuku ku, Tokyo, Japan
    Psychopharmacol Bull 41:164-70. 2008
  8. ncbi Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone
    Takefumi Suzuki
    Department of Neuro Psychiatry, School of Medicine, Keio University, Shinanomachi, Shinjuku ku, Tokyo, Japan
    Hum Psychopharmacol 23:455-63. 2008
  9. ncbi Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report
    T Suzuki
    Department of Neuro Psychiatry, School of Medicine, Keio University, Tokyo, Japan
    J Clin Pharm Ther 32:525-7. 2007
  10. ncbi Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia
    Takefumi Suzuki
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, Japan
    Hum Psychopharmacol 24:628-38. 2009

Collaborators

Detail Information

Publications60

  1. ncbi Novel rating scales for schizophrenia - Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz)
    Takefumi Suzuki
    Keio University, School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Schizophr Res 106:328-36. 2008
    ..Relevant, quick, and user-friendly assessment scales are needed to facilitate measurement-based treatment of schizophrenia...
  2. ncbi Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation
    Takefumi Suzuki
    Department of Neuropsychiatry, Keio University, School of Medicine, Tokyo, Japan
    Psychiatry Res 197:1-6. 2012
    ..While these suggestions provide a pragmatic framework for TRS classification, they need to be tested in future trials...
  3. ncbi Factors associated with response to clozapine in schizophrenia: a review
    Takefumi Suzuki
    Keio University, School of Medicine, Department of Neuropsychiatry, 35, Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Psychopharmacol Bull 44:32-60. 2011
    ..However, factors affecting response to this medication have not been comprehensively reviewed recently...
  4. ncbi Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review
    Takefumi Suzuki
    Keio University, School of Medicine, Department of Neuropsychiatry, 35, Shinanomachi, Shinjuku ku, Tokyo, Japan
    Psychopharmacol Bull 44:18-31. 2011
    ..This paper reviewed which rating scales past studies adopted as an outcome measure in clinical trials for schizophrenia, for which a consensus has been lacking...
  5. ncbi Treatment resistant schizophrenia and response to antipsychotics: a review
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program, Toronto, Ontario, Canada
    Schizophr Res 133:54-62. 2011
    ..There remains a lack of agreement regarding criteria for treatment-resistant schizophrenia (TRS) and definition of response...
  6. ncbi Treatment target in schizophrenia: a critical review and a clinical suggestion
    Takefumi Suzuki
    Keio University, School of Medicine, Department of Neuropsychiatry, Shinjuku ku, Tokyo, Japan
    Psychopharmacol Bull 41:80-102. 2008
    ..Patients with schizophrenia have many problems as well as symptoms, and various rating scales have been in use to address them...
  7. ncbi A potentially aborted neuroleptic malignant syndrome following seclusion against uncontrollable water intoxication
    Takefumi Suzuki
    Department of Neuro Psychiatry, Keio University, School of Medicine, Shinjuku ku, Tokyo, Japan
    Psychopharmacol Bull 41:164-70. 2008
    ..He is now treated with olanzapine, valproate, and lorazepam, with some success. Caution is required for secluding extreme cases of uncontrollable water intoxication...
  8. ncbi Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone
    Takefumi Suzuki
    Department of Neuro Psychiatry, School of Medicine, Keio University, Shinanomachi, Shinjuku ku, Tokyo, Japan
    Hum Psychopharmacol 23:455-63. 2008
    ..To evaluate the effectiveness of antipsychotic polypharmacy in a methodologically sound manner...
  9. ncbi Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report
    T Suzuki
    Department of Neuro Psychiatry, School of Medicine, Keio University, Tokyo, Japan
    J Clin Pharm Ther 32:525-7. 2007
    ..To report the usefulness of antipsychotic dose-reduction for avoiding paralytic ileus in a patient with chronic schizophrenia and comorbid dementia...
  10. ncbi Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia
    Takefumi Suzuki
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, Japan
    Hum Psychopharmacol 24:628-38. 2009
    ..Most difficult inpatients with schizophrenia are in serious needs but obviously underrepresented in clinical trials...
  11. ncbi How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting
    Takefumi Suzuki
    Department of Neuro Psychiatry, School of Medicine, Keio University, 35, Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Psychopharmacology (Berl) 195:285-95. 2007
    ..Evidence on sequential trial with atypical antipsychotics has been scarce...
  12. ncbi A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia
    Takefumi Suzuki
    Department of Neuropsychiatry, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160 8582, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 28:361-9. 2004
    ..By showing successful cases, the authors suggest a possibility of antipsychotic monotherapy with a second-generation agent even for those patients who had been treated with high-dose antipsychotic polypharmacy in vain...
  13. ncbi Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia
    Takefumi Suzuki
    Department of Neuropsychiatry, Keio University, School of Medicine, Tokyo, Japan
    Int Clin Psychopharmacol 18:323-9. 2003
    ..01). Dose reduction is an encouraging strategy to consider for those patients with schizophrenia who have chronically been treated with high-dose antipsychotic polypharmacy, even if judged unavoidable in the past...
  14. ncbi Magnitude of rater differences in assessment scales for schizophrenia
    Takefumi Suzuki
    Department of Neuropsychiatry, School of Medicine, Keio University, Shinjuku ku, Tokyo, Japan
    J Clin Psychopharmacol 30:607-11. 2010
    ..The magnitude of differences described herein seems to be an underestimation, and the baseline scores by the independent new raters might need to be corrected for those by the PICs...
  15. ncbi [Is it valid to concurrently use multiple antipsychotics for patients with schizophrenia?]
    Takefumi Suzuki
    Keio University, School of Medicine, Department of Neuropsychiatry, Japan
    Nihon Shinkei Seishin Yakurigaku Zasshi 25:159-68. 2005
    ..Adding medications upon the emergence of symptoms might be an easy way to treat patients. Such an action should be validated in every case, however, and polypharmacy should be tested against prolonged, tenacious monotherapy...
  16. ncbi Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia
    Takefumi Suzuki
    Department of Neuropsychiatry, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku, Tokyo, 160 8582, Japan
    Psychopharmacology (Berl) 181:566-75. 2005
    ..Taking psychotropic medications is frequently problematic from both consumers' and caregivers' perspective. Occasionally missed doses may lead to pervasive non-adherence with relapse a likely outcome...
  17. ncbi Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia
    Takefumi Suzuki
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    Int J Neuropsychopharmacol 7:133-42. 2004
    ..It is suggested that many instances of antipsychotic polypharmacy is avoidable. The result is compatible with the current treatment recommendations, which dictate the use of a single antipsychotic agent...
  18. ncbi A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia
    Saeko Ikai
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
    J Clin Psychiatry 73:1147-52. 2012
    ..The data are especially scarce for long-acting antipsychotic formulations...
  19. ncbi Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan
    Hiroyuki Uchida
    Keio University, School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Psychiatry Clin Neurosci 63:244-6. 2009
    ..The frequent use of benzodiazepines is a cause for concern because they are not preferred treatment, given their well-known adverse effects especially in the elderly...
  20. ncbi Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey
    Hideaki Tani
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    BMC Oral Health 12:32. 2012
    ..The objective of this study was to examine dental caries and to identify clinical and demographic variables associated with poor dental condition in patients with schizophrenia...
  21. ncbi Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study
    Hiroyuki Uchida
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
    Ther Drug Monit 34:182-7. 2012
    ..Using population pharmacokinetic methods, the authors therefore sought to predict plasma concentrations of risperidone (RIS) plus 9-hydroxyrisperidone (9-OH-RIS) before a dosage change...
  22. ncbi Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program and Multimodal Imaging Group, and Department of Psychiatry, University of Toronto, Ontario, Canada, and Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Br J Psychiatry 199:275-80. 2011
    ..Improvements are greatest in the earlier weeks of antipsychotic treatment of patients with non-resistant schizophrenia...
  23. ncbi Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan
    Hiroyuki Uchida
    Keio University, School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    J Anxiety Disord 23:477-81. 2009
    ..The very high use of anxiolytics in the elderly, especially in the absence of concomitant antidepressant use, is a cause for concern since they are not a preferred long-term treatment strategy given their adverse effects in the elderly...
  24. ncbi Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan
    Hiroyuki Uchida
    Department of Neuropsychiatry, Keio University, School of Medicine, Tokyo, Japan
    Am J Geriatr Psychiatry 16:584-93. 2008
    ..The objective of this study was to better evaluate these age effects on antipsychotic dose prescribed in these patients across a broad age range...
  25. ncbi The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective
    Chisa Tsutsumi
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    Schizophr Res 130:40-6. 2011
    ..The objective of this study was to examine the evolution of antipsychotic switch and polypharmacy in the real-world from a longitudinal perspective...
  26. ncbi Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study
    Yuya Mizuno
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 37:182-7. 2012
    ..The results suggest that sustained D2 receptor occupancy levels of ≥65% may not always be necessary for the maintenance treatment of schizophrenia...
  27. ncbi How successful are physicians in eliciting the truth from their patients? A large-scale Internet survey from patients' perspectives
    Norifusa Sawada
    Department of Psychiatry, Oizumi Hospital, Tokyo, Japan
    J Clin Psychiatry 73:311-7. 2012
    ..We therefore conducted a large-scale Internet survey in an effort to discover how successful physicians are in eliciting the truth from their patients and also to examine reasons for patients' truth-concealing behaviors...
  28. ncbi Persistence and compliance to antidepressant treatment in patients with depression: a chart review
    Norifusa Sawada
    Department of Psychiatry, Saiseikai Central Hospital, Tokyo, Japan
    BMC Psychiatry 9:38. 2009
    ..e., whether patients take doses as instructed). However, no study has yet assessed these two clinically relevant components at the same time in adherence to antidepressant treatment in the clinical outpatient setting...
  29. ncbi Subjective recognition of adverse events with antidepressant in people with depression: a prospective study
    Toshiaki Kikuchi
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
    J Affect Disord 135:347-53. 2011
    ....
  30. ncbi How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review
    Hiroyoshi Takeuchi
    Keio University, School of Medicine, Department of Neuropsychiatry, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    J Psychiatr Res 45:1083-8. 2011
    ..Antipsychotic dose reduction is generally recommended to occur after six months of clinical stabilization despite inadequate evidence. This timing issue was addressed in this study...
  31. ncbi Patient's trust in their psychiatrist: a cross-sectional survey
    Atsumi Minamisawa
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    Eur Arch Psychiatry Clin Neurosci 261:603-8. 2011
    ..Furthermore, this likely holds more true for patients with neurotic disorders...
  32. ncbi Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis
    Hiroyuki Uchida
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, Japan
    Schizophr Bull 37:788-99. 2011
    ....
  33. ncbi Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial
    Shinichiro Nakajima
    Department of Neuropsychiatry, Keio University, School of Medicine, Tokyo, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 35:1983-9. 2011
    ....
  34. ncbi Management of schizophrenia in late life with antipsychotic medications: a qualitative review
    Takefumi Suzuki
    Centre for Addiction and Mental Health, Geriatric Mental Health Program, Toronto, ON, Canada
    Drugs Aging 28:961-80. 2011
    ..However, data on geriatric patients with schizophrenia are generally scarce, particularly for treatment-resistant subpopulations, underscoring the need for more research in this important area...
  35. ncbi Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms
    Hiroyoshi Takeuchi
    Keio University, School of Medicine, Department of Neuropsychiatry, Tokyo, Japan
    Schizophr Res 134:219-25. 2012
    ..Antipsychotic treatment strategy for the maintenance phase of schizophrenia has been inconsistent in the literature. The purpose of this systematic review is to overview recommendations in various guidelines and algorithms...
  36. ncbi Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis
    Hiroyuki Uchida
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
    J Clin Psychopharmacol 31:497-502. 2011
    ....
  37. ncbi Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia
    Monica Hazra
    Centre for Addiction and Mental Health, University of Toronto, Ontario, Canada
    Psychiatry Clin Neurosci 65:676-8. 2011
    ..A three-fold decrease in the prevalence of antipsychotic polypharmacy was observed between 2006 (18.3%) and 2008 (6.6%). Thus, active monitoring of prescriptions with educational interventions could reduce antipsychotic polypharmacy...
  38. ncbi Plasma substance P level in patients with schizophrenia: a cross-sectional study
    Takuto Ishida
    Department of Psychiatry, Sakuragaoka Memorial Hospital, Tokyo, Japan
    Psychiatry Clin Neurosci 65:526-8. 2011
    ..This finding suggests the need for intensive observation for prevention of aspiration pneumonia in heavy smokers who are receiving a higher antipsychotic dose in this senior population...
  39. ncbi Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: a chart review
    Shinichiro Nakajima
    Oizumi Hospital and daggerDepartment of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan
    J ECT 25:178-81. 2009
    ..In this study, we conducted a chart review to examine impacts of the antidepressant switch after the successful ECT on 1-year outcome in patients with TRD...
  40. ncbi Predicting dopamine D₂ receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis
    Hiroyuki Uchida
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
    J Clin Psychopharmacol 31:318-25. 2011
    ..1 (-3.3 to 3.1) and 12.3 (8.8-15.7) for ziprasidone (n = 31), respectively. These findings suggest that D₂ occupancy of antipsychotics could be estimated with a high degree of accuracy using widely available plasma levels...
  41. ncbi Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack: an ideal treatment option in terms of the adverse effect
    Hiroyuki Uchida
    Department of Neuro Psychiatry, School of Medicine, Keio University, Tokyo, Japan
    J Clin Psychopharmacol 26:50-5. 2006
    ..There were no changes in the underlying illness as measured by the PANSS in both groups. Reducing the dose of antipsychotic agents ameliorates VHA and represents the ideal treatment option for patients with VHA...
  42. ncbi Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder
    Hiroyuki Uchida
    Department of Neuropsychiatry, Keio University, School of Medicine, Tokyo, Japan
    J Clin Psychopharmacol 25:545-51. 2005
    ..The combination treatment may be a safe and effective strategy for accelerating antidepressant response...
  43. ncbi Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study
    Hiroyoshi Takeuchi
    Department of Neuropsychiatry, Keio University, School of Medicine, Tokyo, Japan
    Psychiatry Clin Neurosci 64:104-6. 2010
    ..Given known detrimental metabolic and hormonal effects of some atypical antipsychotics, a switch to aripiprazole may warrant serious consideration also in Asian patients who suffer those side-effects...
  44. ncbi Accelerating response to antidepressant treatment in depression: a review and clinical suggestions
    Shinichiro Nakajima
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 34:259-64. 2010
    ..Based on these data, we try to propose both an effective and safe antidepressant treatment strategy to alleviate depressive symptoms at the earliest opportunity...
  45. ncbi Clinical and demographic characteristics associated with postural instability in patients with schizophrenia
    Akihiro Koreki
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
    J Clin Psychopharmacol 31:16-21. 2011
    ....
  46. ncbi Patients' attitudes toward side effects of antidepressants: an Internet survey
    Toshiaki Kikuchi
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Eur Arch Psychiatry Clin Neurosci 261:103-9. 2011
    ....
  47. ncbi Sensitivity to antipsychotic drugs in older adults
    Chloe Leon
    Centre for Addiction and Mental Health, Multimodal Imaging Group, PET Centre, 250 College Street, Toronto, ON M5T1R8, Canada
    Curr Psychiatry Rep 12:28-33. 2010
    ..Implications of recent research findings for individualized pharmacotherapy are discussed...
  48. ncbi Recurrent episodes of perceptual alteration in patients treated with antipsychotic agents
    Hiroyuki Uchida
    Department of Neuro Psychiatry, School of Medicine, Keio University, Tokyo, Japan
    J Clin Psychopharmacol 23:496-9. 2003
    ..We suggest that PPA could manifest itself as an undesirable effect of antipsychotics, especially those of high potency. PPA and OGC may a share common underlying mechanism...
  49. ncbi A tipping point in drug dosing in late-life schizophrenia
    Takashi Tsuboi
    Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, Japan
    Curr Psychiatry Rep 13:225-33. 2011
    ..The age-related antipsychotic sensitivity highlights the importance of finding the lowest possible effective dose of antipsychotic drugs as patients with schizophrenia age to maximize therapeutic effects and minimize side effects...
  50. ncbi Two case reports of successful prevention of overdosing in borderline patients
    Hiroyuki Uchida
    Department of Neuro Psychiatry, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Psychiatry 68:179-82. 2005
    ..Although no perfect method of preventing overdosing is currently available, our method provides an option when psychotropic agents are prescribed for BPD patients in clinical practice...
  51. ncbi Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial
    Yusuke Iwata
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
    J Neurol Sci 315:137-40. 2012
    ..In conclusion, zonisamide may be safe and effective for the treatment of TD associated with antipsychotic treatment. These preliminary findings need to be further explored by larger well-designed trials...
  52. ncbi Coping strategies for antidepressant side effects: An Internet survey
    Toshiaki Kikuchi
    Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan Columbia University, Department of Psychiatry, NY, United States Electronic address
    J Affect Disord 143:89-94. 2012
    ..Patients' coping methods to palliate side effects of antidepressants have not been reported in the literature...
  53. ncbi Deficit status in bipolar disorder: Investigation on prevalence rate and description of seven cases
    Shintaro Nio
    Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan Department of Psychiatry, Tokyo Musashino Hospital, Tokyo, Japan Electronic address
    J Affect Disord 143:248-52. 2012
    ..While the Kraepelinian dichotomy explicitly distinguishes between schizophrenia and bipolar disorder, it remains unclear as to whether a deficit form of bipolar disorder exists...
  54. ncbi Asymptomatic deep vein thrombosis in a patient with major depressive disorder
    Takuto Ishida
    Department of Psychiatry, Sakuragaoka Memorial Hospital, 1 1 1 Renkouji, Tama shi, Tokyo 206 0021, Japan Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Case Rep Psychiatry 2012:261251. 2012
    ..In light of the reported causal relationship between DVT and pulmonary embolism, screening for DVT can be of high clinical value in patients with psychiatric disorders, especially when their physical activity is highly compromised...
  55. ncbi Interventions to reduce antipsychotic polypharmacy: a systematic review
    Hideaki Tani
    Department of Psychiatry, Yamanashi Prefectural Kita Hospital, Yamanashi, Japan
    Schizophr Res 143:215-20. 2013
    ..The objective of this study was to synthesize the clinical evidence to reduce antipsychotic polypharmacy (i.e. use of multiple antipsychotics) in schizophrenia...
  56. ncbi An open-label trial of discontinuing benzodiazepines in patients with chronic schizophrenia
    Shinichiro Nakajima
    J Clin Psychopharmacol 27:401-3. 2007
  57. ncbi Antipsychotic-induced paroxysmal perceptual alteration
    Hiroyuki Uchida
    Am J Psychiatry 160:2243-4. 2003
  58. ncbi The role of trophinin, an adhesion molecule unique to human trophoblasts, in progression of colorectal cancer
    Oi Harada
    Department of Pathology, Shinshu University School of Medicine, Matsumoto, Japan
    Int J Cancer 121:1072-8. 2007
    ..6% of trophinin-positive patients (n = 32). These results suggest that trophinin promotes invasion through a mechanism involving HMGB1/RAGE...
  59. ncbi Antipsychotics-induced hypersensitivity of visual perception
    Hiroyuki Uchida
    Eur Psychiatry 21:343-4. 2006
  60. ncbi Treating a schizophrenic patient with severe tardive dystonia without antipsychotics
    Takefumi Suzuki
    Prog Neuropsychopharmacol Biol Psychiatry 31:1141-2. 2007